Objectives: The underlying mechanism for amphotericin B-induced acute kidney injury (AKI) remains poorly understood and may be immunologically mediated. We assessed whether the development of nephrotoxicity is linked to a distinct cytokine profile in patients receiving amphotericin B deoxycholate (AmBD).
Introduction
Amphotericin B deoxycholate (AmBD) has been the gold standard for treating invasive fungal diseases for many years. However the side effects of nephrotoxicity and infusion-related reactions (IRRs) are often seen, hampering its use in clinical practice. Furthermore, newer antifungal drugs such as the secondgeneration azoles and echinocandins are presently available that have lower toxicity profiles, providing an alternative to AmBD for the first-line treatment of invasive aspergillosis (IA). 1 Nonetheless, amphotericin B retains an important place in the antifungal armamentarium, particularly where healthcare resources are limited, such as in many parts of Asia, where the newer drugs are very much more expensive to purchase. 2 Amphotericin B possesses broad-spectrum activity against most yeasts and moulds that cause opportunistic invasive fungal diseases. 3 In addition, the drug is still considered the first-line treatment for cryptococcosis and histoplasmosis. 4, 5 There have also been treatment failures attributed to resistance to azoles (itraconazole, voriconazole and posaconazole) and echinocandins (caspofungin), necessitating reversion to amphotericin B-based therapies given either alone or in combination to continue therapy. 6 The use of amphotericin B lipid formulations reduces the incidence of toxicity related to AmBD, though nephrotoxicity can still be encountered at higher doses. 7 Hence there remains inherent interest in understanding the mechanisms responsible for amphotericin B-related adverse reactions. Early studies have proposed renal tubular toxicity and afferent arteriolar vasoconstriction as possible physiological factors for amphotericin B-induced nephrotoxicity, but the underlying mechanistic explanation of injury remains poorly understood. The development of IRRs has been attributed to the propensity of AmBD to induce pro-inflammatory cytokines through Toll-like receptor (TLR) 2. 8 On a similar note, the development of drug-induced nephrotoxicity has been described as being immunologically mediated through TLR4, 9 but this has not been studied in the context of AmBD treatment in patients. Moreover, many of the above hypotheses have been derived mainly from in vitro and animal models and remain to be validated in the clinical setting.
Hence we decided to examine this hypothesis and determine whether the occurrence of acute kidney injury (AKI) might be immunologically mediated and linked to the development of a distinct cytokine profile in patients receiving AmBD treatment.
Patients and methods
Patient data were retrieved from the database originally generated for Protocol 150-307 of the Global Comparative Aspergillosis Study, which was a multicentre randomized trial that compared the efficacy of AmBD with that of voriconazole for the primary treatment of IA. The selection of eligible patients for the trial, as well as the case definitions, were as previously detailed, 10 except that we restricted this analysis to patients randomized to receive AmBD as initial therapy. The protocol had approval from the appropriate institutional review boards and written consent was obtained from all of the patients.
In this study, AKI was defined as a 2-fold increase in serum creatinine during AmBD therapy in relation to the baseline level before starting antifungal treatment, or a level .3 mg/dL (265 mmol/L) if the baseline value was .1.5 mg/dL (133 mmol/L). 10, 11 Patients with baseline serum creatinine levels .2.5 mg/dL (221 mmol/L) were excluded from the study.
Cytokine measurements were performed as part of a recent study on cytokine trends in IA, from which further sub-analyses were performed. 12 Specifically, circulating concentrations of interleukin (IL)-6, IL-8 and IL-10 were measured at baseline, week 1 and week 2 from serum specimens obtained serially at recruitment and after the start of treatment with AmBD. To minimize variable degradation of the analytes, the specimens were stored at 2208C before assay. Multiple freeze -thaw cycles were avoided and all specimens were analysed at the same thaw cycle. To ensure objectivity, the specimens were coded and cytokine measurement was performed blinded. The results, together with the corresponding clinical data, were put together only at the stage of analysis. IL-6, IL-8 and IL-10 concentrations were measured using commercial sandwich ELISA kits (Pelikine Compact, CLB, Amsterdam, The Netherlands) according to the instructions of the manufacturer. The lower detection limits of the assays were 3.1, 16 and 4.7 pg/mL for IL-6, IL-8 and IL-10, respectively. The inter-assay coefficient of variation was 14%. Serial cytokine trends were correlated with the development of renal impairment.
The comparison of demographic and clinical characteristics between those with and without AKI was made using Fisher's exact test in the case of categorical variables and Student's t-test in the case of continuous variables, such as age. The Cox proportional hazards model was implemented to evaluate the association between cytokine trends (IL-6, IL-8 and IL-10) and the time to development of nephrotoxicity, using the category of patients with decreasing cytokine trend from baseline to week 1, and then from week 1 to week 2 (category ' / ' as depicted in Table 2 ) as the reference. The magnitude of effect was quantified using the hazard ratio (HR) estimate and its associated 95% CI. All statistical evaluations were performed using STATA release 12.0 (StataCorp, College Station, TX, USA) assuming a two-sided test at the 5% level of significance. Table 1 summarizes the demographic characteristics of the study cohort and treatment-related outcomes. Of the 58 patients who had received AmBD as primary therapy, 27 (46.6%) developed nephrotoxicity during the course of treatment. The patients' age, sex, site of infection, absolute neutrophil count and underlying haematological disease did not have a major influence on the onset of renal impairment. Patients who developed impaired renal function did not have significantly worse outcomes in terms of clinical response or survival at week 12 (end of trial).
Results
The median circulating cytokine level (with range) measured for IL-6 was 12 pg/mL (3.1-3740) at baseline, 6.3 pg/mL (3.1 -417) at week 1 and 4.4 pg/mL (3.1 -122) at week 2. IL-8 levels at the above three timepoints were 138.5 (82 -6514), 80.5 (44 -3713) and 78 pg/mL (46 -1575), respectively, while median IL-10 was largely unchanged at 4.7 pg/mL throughout (range 4.7 -99 at baseline, 4.7 -48 at week 1 and 4.7 -44 at week 2). The correlation between circulating absolute levels of IL-6, IL-8 and IL-10 and the onset of AKI was weak (data not shown).
Cytokine concentration trends from baseline to week 1 and from week 1 to week 2 were analysed in relation to the development of AKI (see Table 2 ). The P value was 0.026 for the overall effect of IL-6 on time to development of AKI. Patients with persistently elevated levels of proinflammatory IL-6 after 1 week of AmBD treatment were at higher risk of developing nephrotoxicity compared with patients who had a decreasing cytokine trend (Table 2) . Notably, patients with IL-6 cytokine profile ' / ' (increasing IL-6 from baseline to week 1 and declining IL-6 from week 1 to week 2) had an HR of 6.93 (95% CI 1.81-26.47, P value 0.005) for the development of AKI. On a similar note, other patients who did not have interval drops in IL-6 levels (' / ' and 0/0) had a 2.74-to 3.46-fold increased likelihood of developing nephrotoxicity. IL-8 trends were less specific, though again persistently increasing IL-8 levels were linked to AKI (HR 3.84, P value 0.053). On the other hand, the counterinflammatory cytokine IL-10 trends were not linked to predisposition to AmBD-associated renal injury.
Discussion
Inflammation plays a central role in the pathogenesis of druginduced kidney injury. 13 This is mediated through the expression of cytokines upon activation of TLRs located on the renal parenchymal and tubulointerstitial cells. The net inflammatory response entails a coordinated balance between the proinflammatory and counter-inflammatory mediators; a relative exuberance of the former predisposes to tissue injury. While much of this knowledge has been gained from the study of cisplatin-induced nephrotoxicity, little is known in the setting of amphotericin B.
The pro-inflammatory nature of amphotericin B, in particular AmBD, has been characterized. This is thought to be mediated through engagement of TLR2 and TLR4, resulting in activation of NF-kB and the resulting production of cytokines.
14,15 Our findings here demonstrate that, in the setting of patients receiving AmBD therapy for IA, temporal trends of pro-inflammatory cytokines have greater clinical significance than absolute levels. Here, we showed that an early rise in IL-6 at 1 week of antifungal End of randomized therapy (EORT) response: clinical response as assessed by the DRC at a pre-specified secondary timepoint, reached when AmBD was ceased and the patient was switched to another licensed antifungal therapy. The P value for overall effect of IL-6 on time to development of AKI is 0.026. c In these 19 patients grouped in the 'unchanged' category, 12 subjects had a '0/0' trend, i.e. no change in cytokine level from baseline to week 1, and from week 1 to week 2, 5 subjects had a ' /0' trend, 1 subject had a '0/ ' trend and 1 subject had a '0/ ' trend. Of the 11 patients who developed AKI in this category, 10 subjects had either a '0/0' or '0/ ' trend.
Cytokine trends in amphotericin B nephrotoxicity treatment was linked to a 2.74-to 6.93-fold increased likelihood of developing AmBD-associated AKI. A non-receding/unchanged IL6 trend between baseline and week 2 yielded a similar, albeit reasonably lower, increased AKI risk of 3.46-fold. Persistently elevated IL-8 was also linked to a tendency towards nephrotoxicity. On the other hand, the profile of counter-inflammatory IL-10 was not helpful in this setting.
Before the findings of this patient study, our understanding of the mechanisms underlying drug-induced or ischaemic renal injury had come largely from in vitro and mouse experiments. The TLR4 signalling pathway was implicated in the pathogenesis of cisplatin-induced AKI; TLR4 2/2 mice had less nephrotoxicity in comparison with corresponding wild-type controls, which had higher IL-6 and KC (IL-8-equivalent) murine cytokine levels. 9 The presence of endotoxins in the setting of concurrent infection with background cisplatin administration led to enhanced elaboration of pro-inflammatory cytokines, resulting in an increased propensity to AKI. 16 On a similar note, cyclosporine A-related nephrotoxicity had been linked to IL-6-mediated renal endothelial damage. 17 Other studies had also linked high serum IL-6 levels (at +48 h) with the development of AKI in critical illness. Results from our clinical study here corroborated the above findings, though none had been studied in the context of amphotericin B-associated nephrotoxicity. On the other hand, while IL-10 had been thought to be an important regulatory mediator against a proinflammatory milieu and possibly to have a protective role against AKI, 18 we found circulating IL-10 levels to be generally low and of limited utility. This may be attributable to the attenuated immunogenicity of Aspergillus in the production of IL-10, as had been observed by ourselves previously. 12, 19 Nonetheless, the association of the cytokine trends described above with the development of nephrotoxicity in the clinical cohort here was admittedly less compelling than the findings of in vitro and mice experiments. This was not unanticipated, given the complexity of such patients, whereby the net immune response was also influenced by the underlying concurrent disease processes as well as medications. On the other hand, there is a requirement to attempt to have such postulated disease mechanisms validated in patients. This subcohort of patients receiving AmBD in the Global Comparative Aspergillosis Study provided the unique setting for such a study to be made.
As new light is shed on the mechanism of amphotericin B-induced nephrotoxicity through the signalling pathways that mediate tissue inflammation, it is hoped that novel management strategies can be developed to minimize the adverse effects of this time-tested antifungal agent. One such measure may be the use of N-acetylcysteine, 20 which, in line with its utility in contrast-induced nephropathy, also possesses anti-inflammatory therapeutic properties. Our findings here provide part of the rationale for considering the selective use of immune modulators as adjuncts to curtail immune-mediated pathology and as the basis for further clinical studies in this field.
